Liposomal irinotecan, capecitabine and enlonstobart with short radiation for rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of short-course radiation, two chemotherapy drugs (liposomal irinotecan and capecitabine), and an immunotherapy drug (Enlonstobart) for people with locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have locally advanced rectal adenocarcinoma (cancer that started in gland cells and has grown into deeper layers or nearby lymph nodes, but hasn’t spread far).
- The lower edge of the tumor is within about 4 inches (10 cm) of your anal opening.
- You have not received any prior treatment for this rectal cancer, such as radiation, chemo, or surgery.
- You are in generally good health (able to do daily activities) and your blood counts, liver, and kidney function are within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a short course of radiation with chemotherapy, targeted therapy, and immunotherapy before surgery for locally advanced rectal cancer. It aims to shrink the tumor and improve outcomes.
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
This trial tests a shorter radiation course combined with two chemotherapy drugs and an immunotherapy drug for people with locally advanced rectal cancer that is microsatellite stable. The goal is to shrink the tumor before surgery, which may improve outcomes with fewer side effects.
This trial tests a new combination for rectal cancer that hasn't spread far: a short course of radiation followed by two drugs (AK112 and CAPOX). The goal is to shrink the tumor before surgery and possibly avoid more aggressive treatments.
This trial tests a new combination of treatments (radiation, immunotherapy, and two chemotherapy drugs) given before surgery for people with a specific type of locally advanced rectal cancer that is close to the anus. The goal is to see if this approach is safe and effective.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
Hear when a new Advanced Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.